HC Wainwright & Co. Downgrades Longboard Pharmaceuticals to Neutral, Lowers Price Target to $60

Benzinga · 10/15 17:23
HC Wainwright & Co. analyst Patrick Trucchio downgrades Longboard Pharmaceuticals (NASDAQ:LBPH) from Buy to Neutral and lowers the price target from $80 to $60.